{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:41:45Z","timestamp":1784238105032,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is a well-established therapy for advanced Hodgkin\u2019s lymphoma (HL). However, the recently completed ECHELON-1 trial showed potential net clinical benefit for brentuximab vedotin (BREN+AVD) compared to ABVD as frontline therapy in patients with advanced Hodgkin\u2019s lymphoma. The objective of this analysis is to determine whether, on current evidence, BREN+AVD is cost-effective relative to ABVD as frontline therapy in patients with advanced HL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We constructed a probabilistic Markov model with two arms and six mutually exclusive health states, using six-month\u2009cycle lengths, and a 15-year time horizon. Time-dependent transition probabilities were calculated from \u2018real-world\u2019 data collected by the BC Cancer\u2019s Centre for Lymphoid Cancer database or from the literature for ABVD. Time-dependent transition probabilities for BREN+AVD were taken from the ECHELON-1 trial. We estimated the incremental cost and effects per patient of each therapy and calculated the incremental cost-effectiveness ratio (ICER). Costs were measured in 2018 Canadian dollars and effects measured in quality-adjusted life years (QALYs). A probabilistic analysis was used to generate a cost-effectiveness acceptability curve (CEAC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The incremental cost between standard therapy with ABVD and therapy with BREN+AVD was estimated to be $192,336. The regimen of BREN+AVD resulted in a small benefit in terms of QALYs (0.46 QALYs). The estimated ICER was $418,122 per QALY gained. The probabilistic analysis suggests very few (8%) simulations fall below $100,000 per QALY. Even at a threshold of $200,000 per QALY gained, there was only a 24% chance that BREN+AVD would be considered cost-effective. Sensitivity analyses evaluating price reductions for brentuximab showed that these reductions needed to be in excess of 70% for this regimen to be cost-effective at a threshold of $100,000 per QALY.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>There may be\u00a0a clinical benefit associated with BREN+AVD, but on current evidence the benefit is not adequately substantive compared to ABVD therapy given the cost of brentuximab vedotin. Agencies responsible for making decisions about BREN+AVD as frontline therapy for patients with advanced HL should consider whether they are willing to implement this treatment given the current uncertainty and cost-benefit profile, or negotiate substantial price-reductions from the manufacturer should they choose to reimburse.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07374-3","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T14:02:55Z","timestamp":1602597775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin\u2019s lymphoma: a probabilistic analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-3785","authenticated-orcid":false,"given":"A. J. N.","family":"Raymakers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Regier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"issue":"9","key":"7374_CR1","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1503\/cmaj.191292","volume":"192","author":"DR Brenner","year":"2020","unstructured":"Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199\u2013205.","journal-title":"CMAJ"},{"key":"7374_CR2","volume-title":"Canadian Cancer Statistics","author":"Canadian Cancer Statistics Advisory Committee","year":"2019","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics. Toronto: Canadian Cancer Society; 2019. [cited 2020 Mar 31]. Available from: www.cancer.ca\/Canadian-Cancer-Statistics-2019-EN."},{"key":"7374_CR3","doi-asserted-by":"crossref","unstructured":"Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States. Adv Hematol. 2011;2011 [cited 2020 Mar 31]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3010617\/.","DOI":"10.1155\/2011\/725219"},{"issue":"1","key":"7374_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/asheducation-2005.1.239","volume":"2005","author":"JM Connors","year":"2005","unstructured":"Connors JM. Evolving approaches to primary treatment of Hodgkin lymphoma. Hematology. 2005;2005(1):239\u201344.","journal-title":"Hematology"},{"key":"7374_CR5","doi-asserted-by":"crossref","unstructured":"Richardson SE, McNamara C. The Management of Classical Hodgkin\u2019s Lymphoma: Past, Present, and Future [Internet]. 2011, Advances in Hematology. Hindawi; 2011. p. e865870. [cited 2020 Mar 31]. Available from: https:\/\/www.hindawi.com\/journals\/ah\/2011\/865870\/.","DOI":"10.1155\/2011\/865870"},{"issue":"25","key":"7374_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374(25):2419\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"7374_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/PPO.0000000000000333","volume":"24","author":"JM Connors","year":"2018","unstructured":"Connors JM. Advanced-stage Hodgkin lymphoma: new approaches based on novel therapeutic agents or treatment intensification. Cancer J. 2018;24(5):230.","journal-title":"Cancer J"},{"issue":"3","key":"7374_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","volume":"32","author":"GP Canellos","year":"2014","unstructured":"Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7374_CR9","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812\u201326.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7374_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"7374_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1517\/14712598.2012.718328","volume":"12","author":"B Pro","year":"2012","unstructured":"Pro B, Perini GF. Brentuximab vedotin in Hodgkin\u2019s lymphoma. Expert Opin Biol Ther. 2012;12(10):1415\u201321.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"7374_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"12","key":"7374_CR13","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562\u20136.","journal-title":"Blood"},{"issue":"8","key":"7374_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2009.25.4367","volume":"28","author":"JJ Cerci","year":"2010","unstructured":"Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CCG, Soares J, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin\u2019s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28(8):1415\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7374_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007.","journal-title":"PLoS One"},{"issue":"12","key":"7374_CR16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","volume":"91","author":"HM Blommestein","year":"2012","unstructured":"Blommestein HM, Verelst SGR, Huijgens PC, Blijlevens NMA, Cornelissen JJ, Uyl-de Groot CA. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol. 2012;91(12):1945\u201352.","journal-title":"Ann Hematol"},{"issue":"6","key":"7374_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","volume":"56","author":"P Swinburn","year":"2015","unstructured":"Swinburn P, Shingler S, Acaster S, Lloyd A, Bonthapally V. Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839\u201345.","journal-title":"Leuk Lymphoma"},{"key":"7374_CR18","volume-title":"Canadian Agency for Drugs and Technologies in Health","author":"Guidelines for the Economic Evaluation of Health Technologies in Canada [Internet]","year":"2017","unstructured":"Guidelines for the Economic Evaluation of Health Technologies in Canada [Internet]. Canadian Agency for Drugs and Technologies in Health; 2017. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf."},{"key":"#cr-split#-7374_CR19.1","doi-asserted-by":"crossref","unstructured":"Jackson C. flexsurv: A Platform for Parametric Survival Modeling in R. J Stat Softw. 2016;70","DOI":"10.18637\/jss.v070.i08"},{"key":"#cr-split#-7374_CR19.2","unstructured":"(8) [cited 2020 Mar 31]. Available from: http:\/\/www.jstatsoft.org\/v70\/i08\/."},{"key":"7374_CR20","first-page":"797","volume-title":"A second course in statistics: regression analysis","author":"W Mendenhall","year":"2012","unstructured":"Mendenhall W, Sincich T. A second course in statistics: regression analysis. 7th ed. Boston: Prentice Hall; 2012. p. 797.","edition":"7"},{"key":"7374_CR21","unstructured":"Siegel AF. Practical Business Statistics [Internet]: Elsevier; 2017. p. 642. [cited 2019 Oct 1]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/C20150004634."},{"key":"7374_CR22","unstructured":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Mar 31]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01712490."},{"issue":"26","key":"7374_CR23","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798\u2013804.","journal-title":"Blood"},{"key":"7374_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ejca.2018.09.021","volume":"104","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Prasad V. Brentuximab vedotin for frontline Hodgkin lymphoma: how much will a successful trial cost patients and payers? Eur J Cancer. 2018;104:252\u20133.","journal-title":"Eur J Cancer"},{"issue":"2","key":"7374_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13696998.2018.1542599","volume":"22","author":"TE Delea","year":"2019","unstructured":"Delea TE, Sharma A, Grossman A, Eichten C, Fenton K, Josephson N, et al. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ. 2019;22(2):117\u201330.","journal-title":"J Med Econ"},{"issue":"33","key":"7374_CR26","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.18.00122","volume":"36","author":"SF Huntington","year":"2018","unstructured":"Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-effectiveness analysis of Brentuximab Vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma. J Clin Oncol. 2018;36(33):3307\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7374_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cncr.32455","volume":"126","author":"AJN Raymakers","year":"2020","unstructured":"Raymakers AJN, Regier DA, Peacock SJ. Health-related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan-Canadian oncology drug review. Cancer. 2020;126(1):148\u201355.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07374-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07374-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:21:45Z","timestamp":1634091705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07374-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7374"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07374-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this study was obtained by the University of British Columbia \u2013 BC Cancer Research Ethics Board (H18\u201300490).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Adam Raymakers reports having received compensation from the Canadian Agency for Drugs and Technologies in Health (specifically from the pan-Canadian Oncology Drug Review for providing economic guidance about oncology drug submissions). Dean Regier has received funding unrelated to this work for conference travel from Illumina and honoraria from Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"992"}}